TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01223339
Drug: Ertugliflozin
Normalized name: Ertugliflozin
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ertugliflozin 25 mg tablets administered once daily in the fed state for 7 days
Study: NCT00418704
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tarceva (150 mg) is a pill you take once a day -- every day
Study: NCT00418704
Drug: taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taxotere® (docetaxel) is given intravenously (I.V.) into the vein. Taxotere® chemotherapy treatment takes about one hour, and usually people receive treatments every three weeks.
Study: NCT02599311
Drug: Tolterodine
Normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolterodine tartrate can improve patients' LUTS.
Study: NCT00731861
Drug: Paclitaxel plus PTK787
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be given on days 1 and 15 over 28 days in cycle 1 with PTK787 on days 3 to 28. PTK787 WILL BE TAKEN AT NIGHT.~In cycle 2 and beyond, paclitaxel will be given on days 1, 8 and 15 every 28 days . PTK787 will be taken orally NIGHTLY.
Study: NCT01704508
Drug: Dihydroartemisinin-piperaquine
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03135912
Drug: Terbinafine Hydrochloride
Normalized name: Terbinafine Hydrochloride
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical terbinafine hydrochloride cream.
Study: NCT03599778
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX + apatinib's MTD
Study: NCT00006131
Drug: Valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01227967
Drug: Oseltamivir
Normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
Study: NCT00480857
Drug: Docetaxel (Taxotere)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.
Study: NCT02781792
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: -Given standard of care
Study: NCT00092144
Drug: MK0476, montelukast sodium / Duration of Treatment: 4 weeks
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02831491
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT02831491
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered IV
Study: NCT00651118
Drug: azelastine Hcl
Normalized name: azelastine HCl
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: azelastine Hcl 548 mcg
Study: NCT04150289
Drug: Farydak
Normalized name: Farydak
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: non-interventional study
Study: NCT00921115
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.
Study: NCT00921115
Drug: Anastrazole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles
Study: NCT01527045
Drug: Atorvastatin Calcium
Normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01527045
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01527045
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01527045
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT00649285
Drug: Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg, single dose fed
Study: NCT01481350
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients will receive a dose of 10 mg every 8 hours, for a maximum time of 72 hours.
Study: NCT01696799
Drug: Econazole Nitrate
Normalized name: Econazole Nitrate
DrugBank: Econazole (DB01127)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03462641
Drug: Flumazenil
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg in 10cc normal saline
Study: NCT00651118
Drug: azelastineHcl / fluticasone propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: azelastine Hcl 548 mcg / fluticasone propionate 200 mcg
Study: NCT01736423
Drug: YM060
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00606411
Drug: Topiramate or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules
Study: NCT00237666
Drug: Ziprasidone
Normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ziprasidone 20-60 mg BID, taken orally.
Study: NCT02443337
Drug: Necitumumab
Normalized name: Necitumumab
DrugBank: Necitumumab (DB09559)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT00920361
Drug: Follitropin beta
Normalized name: Follitropin Beta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Normally, Follistim Injection 150 or 225 IU will be administered (s.c. or i.m.) once a day for 4 days as follitropin beta (genetical recombination). The dosage will be adapted to growth of follicles (75-375 IU for 6-12 days, in general). If more than 3 follicles of mean diameter 16-20 mm are confirmed by ultrasound tomography, ovulation will be stimulated by using Human Chorionic Gonadotropin (hCG) drugs.
Study: NCT00002509
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002509
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002509
Drug: mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03479450
Drug: surfactant
Normalized name: Surfactant
DrugBank: Recombinant surfactant protein D (DB18438)
Approvals — FDA: no, EMA: no, PMDA: no
Description: surfactant is given when neonatal respiratory distress syndrome is diagnosed
Study: NCT02151903
Drug: DI-Leu16-IL2
Normalized name: di-isopropylammonium
DrugBank: Propyl acetate (DB01670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
Study: NCT01927406
Drug: Timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol topical eye drop will be administered in Prostaglandin Analog vs Timolol arm only, in patients with elevated intraocular pressure in both eyes.
Study: NCT01852942
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will start with 50 mg of losartan by mouth daily. The dose will be increased to 100 mg by mouth daily after 14 days. The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.
Study: NCT00874354
Drug: Intracoronary Transplantation of Bone Marrow Stem Cells
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary application of autologous bone marrow-derived mononuclear cells in infarct artery 3 - 14 days after PCI for acute myocardial infarction.
Study: NCT02053181
Drug: Cadazolid
Normalized name: Cadazolid
DrugBank: Cadazolid (DB11847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadazolid was provided as dry powder for oral suspension (Amber glass bottles of 60 mL). The powder was reconstituted with tap water by a pharmacist immediately prior to dispensing to subjects.
Study: NCT00616460
Drug: Bivalirudin
Normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bivalirudin: loading dose 0.75mg/kg bolus During procedure: 1.75mg/kg/hour. UFH: loading dose 60 Units /kg During procedure: keeping ACT \< 250
Study: NCT02635828
Drug: Palonosetron 0.075 mg IV
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.
Study: NCT02635828
Drug: Dexamethasone 10 mg IV
Normalized name: dexamethasone phosphate 10 MG/ML
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.
Study: NCT02635828
Drug: Promethazine 25 mg IV
DrugBank: Promethazine (DB01069)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.
Study: NCT00308503
Drug: eplivanserin (SR46349)
Normalized name: Eplivanserin
DrugBank: Eplivanserin (DB12177)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT00712829
Drug: 123-I-MIP-1072
Normalized name: MIP-1095 I-123
DrugBank: MIP-1095 I-123 (DB12994)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mCi intravenous injection given one time during the study
Study: NCT00712829
Drug: 123-I-MIP-1095
Normalized name: MIP-1095 I-123
DrugBank: MIP-1095 I-123 (DB12994)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mCi intravenous injection given one time during the study
Study: NCT03054545
Drug: Iguratimod
Normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Iguratimod 25mg twice a day, oral administrated.
Study: NCT00651118
Drug: fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: fluticasone propionate 200 mcg
Study: NCT03503786
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5 i.v. every 3 weeks for 6 - 8 cycles
Study: NCT03503786
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2 i.v. every 3 weeks for 6-8 cycles
Study: NCT03503786
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 10 mg/kg every 3 weeks for 6-8 cycles + Avelumab 10 mg/kg every 14 days until disease progression or unacceptable toxicity
Study: NCT03679780
Drug: BQ-788
Normalized name: BQ-788
DrugBank: BQ-788 (DB17984)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention is aimed at blocking endothelin type B receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
Study: NCT03679780
Drug: BQ-123
Normalized name: BQ-123
DrugBank: BQ-123 (DB12054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention is aimed at blocking endothelin type A receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
Study: NCT03679780
Drug: L-Arginine
Normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A substrate that is administered to increase endogenous nitric oxide production. The infusion rate will be 2 µl/min
Study: NCT03679780
Drug: Sodium Nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
Study: NCT03679780
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer will serve as the control site. The infusion rate will be 2 µl/min
Study: NCT03852303
Drug: ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: evaluate effect of ivermectin on frequency of seizures
Study: NCT02506855
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01881230
Drug: nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-Paclitaxel 125 mg/m\^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.
Study: NCT01881230
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration
Study: NCT01881230
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m\^2 on Days 1 and 8 of each 21-day treatment cycle.
Study: NCT02232425
Drug: IX-01
Normalized name: Hematoporphyrin ix
DrugBank: Hemoporfin (DB16183)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01012622
Drug: Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OROS methylphenidate hydrochloride (HCL) will be given orally once daily at an initial dose of 18 milligram (mg) for participants below 30 Kilogram (kg) and 27 mg for those over 30 kg of body weight. The dose will be increased by 9 mg or 18 mg every week for up to Week 8, followed by a maximum maintenance dose of 54 mg orally once daily up to Week 12 during which the dose can be decreased by 9 mg depending on tolerability.
Study: NCT02631863
Drug: Aminolaevulinic acid
DrugBank: Laevulinic Acid (DB02239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminolaevulinic acid with illumination
Study: NCT01047956
Drug: Methadone; NAC
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methadone NAC
Study: NCT01047956
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methadone
Study: NCT00006209
Drug: Tucaresol
Normalized name: Tucaresol
DrugBank: Tucaresol (DB13027)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01591291
Drug: Ondansetron + Brief Behavioral Enhancement Treatment
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron 4ug/kg twice daily
Study: NCT01160068
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin Tablets 1000 mg
Study: NCT01160068
Drug: Glucophage
Normalized name: Glucophage
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Glucophage 1000 mg tablets of Bristol-Myers Squibb
Study: NCT03440515
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone treatment for severe skin rash induced by imatinib
Study: NCT01843166
Drug: Premarin vaginal cream
Normalized name: Premarin Vaginal Product
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2g at bedtime twice weekly
Study: NCT02201329
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine (subcutaneous)
Study: NCT02201329
Drug: Volasertib
Normalized name: Volasertib
DrugBank: Volasertib (DB12062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib escalating doses (intravenous)
Study: NCT00625625
Drug: isosulfan blue
Normalized name: Isosulfan Blue
DrugBank: Isosulfan blue (DB09136)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01836536
Drug: Bevacizumab standard of care
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard treatment associated with circulating leucocytes (blood samplings)
Study: NCT03860428
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the medical treatment arm the in-tention is to close the ductus arteriosus.
Study: NCT02560337
Drug: Cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00078026
Drug: Apomine
Normalized name: Apomine
DrugBank: Apomine (DB12276)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04113863
Drug: all-trans retinoic acid
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
Study: NCT02198859
Drug: Lithium Carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03235921
Drug: Nitroglycerin patch 5mg
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: application of the nitroglycerin patch 5 mg to each patient in nitroglycerin group
Study: NCT01538576
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prescribed by the physicians as a result of normal clinical practice
Study: NCT04916392
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5ml of 1.33% liposomal bupivacaine with 5 ml of 0.9% normal saline will be given to treatment group.
Study: NCT02521038
Drug: Brilinta
Normalized name: Brilinta
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90mg bid as a treatment for Acute coronary syndrome. Dose and Duration can be adjusted by the primary physician.
Study: NCT00633087
Drug: 2-deoxyglucose
Normalized name: 2-DEOXYGLUCOSE
DrugBank: 2-deoxyglucose (DB08831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg of 2-deoxyglucose administered orally on a daily schedule for two weeks (Days 1-14) of a three week (21 Day) cycle.
Study: NCT03715140
Drug: Crucumin
Normalized name: Cucumis melo extract
DrugBank: Cumin (DB10864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of the effect of Crucumin in patients with osteoarthritis
Study: NCT02799758
Drug: NK-104-CR
Normalized name: NK Cells
DrugBank: Natural Killer Cell (DB15721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK-104-CR 8 mg for 52 weeks
Study: NCT02799758
Drug: Placebo (for Livalo® IR)
Normalized name: Livalo
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Livalo® IR 4 mg placebo for 52 weeks
Study: NCT04113863
Drug: Anastrozole 1mg
Normalized name: ANASTROZOLE 1MG TAB
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole will be administered orally at the dosage of 1 mg/die.
Study: NCT00644969
Drug: varenicline (CP-526,555)
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One week of titration up to 1mg bid and 11 weeks of dosing at 1mg bid
Study: NCT00697515
Drug: LDX
Normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral, 30, 50, or 70 mg once-daily for 4 weeks during dose optimization, and then for 1 week during each crossover during the adult workplace environment setting
Study: NCT04073758
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Comparing effects of remifentanil versus dexmedetomidine
Study: NCT02436759
Drug: RVL-1201
Normalized name: ALLANTOIN 5 g in 100 mL TOPICAL CREAM [RVLAIM SILICONE SCAR Cream]
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RVL-1201 Ophthalmic Solution 0.1%
Study: NCT02292290
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 week lead-in 0.6mg Liraglutide OD up to 1.2mg OD after 2 weeks if poor response
Study: NCT02292290
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 week lead-in 0.6mg Liraglutide OD up to 1.2mg after two weeks if poor response.
Study: NCT02292290
Drug: Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As per clinical guidelines for prescription
Study: NCT03054857
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After skin incision, the dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
Study: NCT04405999
Drug: Bromhexine Hydrochloride
Normalized name: bromhexine hydrochloride
DrugBank: Bromhexine (DB09019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical personnel at risk for COVID-19 infection will receive study medication for 14 days
Study: NCT01776788
Drug: insulin lispro injection, exenatide injection
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: First, Patients in the exenatide group will receive short-term continuous subcutaneous insulin (CSII)therapy. The doses will be titrated every day in order to attain the glycaemic goal which is defined as a fasting capillary blood glucose of less than 6.1 mmol/L and capillary blood glucose at 2 h after each of three meals of less than 8.0 mmol/L. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then, patients will Sequential be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 8 weeks. After interventions will be stopped, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly